Xiong, Jing
Kang, Seong Su
Wang, Zhihao
Liu, Xia
Kuo, Tan-Chun http://orcid.org/0000-0001-5301-755X
Korkmaz, Funda http://orcid.org/0000-0002-9174-8369
Padilla, Ashley http://orcid.org/0000-0003-4877-5465
Miyashita, Sari
Chan, Pokman
Zhang, Zhaohui
Katsel, Pavel http://orcid.org/0000-0001-8076-0162
Burgess, Jocoll
Gumerova, Anisa
Ievleva, Kseniia
Sant, Damini
Yu, Shan-Ping http://orcid.org/0000-0003-1335-1398
Muradova, Valeriia http://orcid.org/0000-0003-3257-0780
Frolinger, Tal
Lizneva, Daria
Iqbal, Jameel
Goosens, Ki A. http://orcid.org/0000-0002-5246-2261
Gera, Sakshi
Rosen, Clifford J.
Haroutunian, Vahram http://orcid.org/0000-0001-5860-2512
Ryu, Vitaly
Yuen, Tony
Zaidi, Mone
Ye, Keqiang http://orcid.org/0000-0002-7657-8154
Article History
Received: 16 July 2020
Accepted: 25 January 2022
First Online: 2 March 2022
Competing interests
: M.Z. is listed as an inventor on issued patents on inhibiting FSH for the prevention and treatment of osteoporosis and obesity: US patent numbers 5,436,285 (1995, awarded to Icahn School of Medicine at Mount Sinai (ISMMS)), 5,674,887 (1997, awarded to ISMMS and University of Pittsburgh), 8,435,948 (2013, awarded to ISMMS) and 11,034,761 (2021, awarded to ISMMS). M.Z. is also listed as an inventor on a pending patent application on composition and use of humanized monoclonal anti-FSH antibodies. These patents are owned by ISMMS, and M.Z. would be recipient of royalties according to institutional policy. M.Z. and K.Y. are listed as inventors of a pending patent application on the use of FSH as a target for preventing Alzheimer’s disease. The latter patent is jointly owned by ISMMS and Emory University, and M.Z. and K.Y. would be recipient of royalties according to institutional policy. The other authors declare no competing interests.